Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
12:01am, Tuesday, 04'th Nov 2025
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
Novo Nordisk's Wegovy could soon have a new sales outlet in the U.S.
06:23pm, Monday, 03'rd Nov 2025
Telehealth company Hims & Hers says it is in “active discussions” with Novo Nordisk about selling Wegovy.
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
04:35pm, Monday, 03'rd Nov 2025
Hims & Hers Health, Inc. (NYSE:HIMS) shares popped after the company released its third-quarter earnings report after Monday's closing bell. Hims said it is in active discussions to make Novo Nordisk
Did Novo Nordisk Just Say "Checkmate" to Pfizer?
01:23pm, Monday, 03'rd Nov 2025
Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk.
Novo Nordisk says Metsera bid won't raise antitrust issues
12:04pm, Monday, 03'rd Nov 2025
Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
11:39am, Monday, 03'rd Nov 2025
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera
09:19am, Monday, 03'rd Nov 2025
Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.
Pfizer files second lawsuit against Metsera, Novo Nordisk
08:07am, Monday, 03'rd Nov 2025
Pfizer Inc said on Monday it has filed a second lawsuit against Metsera , its controlling shareholder, and Novo Nordisk in a Delaware federal court, accusing the Danish drugmaker of anticompetitive co
Novo Nordisk: Governance Shakeup Amid Broader Headwinds
05:55am, Monday, 03'rd Nov 2025
Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. NVO's struggles are not solely due to sector weakness, as the Healthcare sector (XLV) is up
Novo Nordisk: Desperate Move
02:46am, Monday, 03'rd Nov 2025
Novo Nordisk made a surprise bid to acquire Metsera, aiming to strengthen its position in the weight-loss drug market. NVO's offer is considered superior to Pfizer's, providing more upfront cash and s
LLY's GLP-1 Pill Revenue Catalyst, NVO Keeps Pace in Industry Race
04:00pm, Sunday, 02'nd Nov 2025
Christine Short and Scott Zari cover Eli Lilly (LLY) earnings and the future of GLP-1 drugs. Christine emphasizes the global demand for these drugs, as evidenced by higher international revenue, and w
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.
Global week ahead: Is Novo Nordisk past 'peak uncertainty'?
03:04am, Sunday, 02'nd Nov 2025
Danish pharmaceutical group Novo Nordisk will release its third-quarter earnings on Wednesday. CNBC's Charlotte Reed will travel to Copenhagen to speak with the company's new CEO after a bumpy few mon
Pfizer sues to block Novo Nordisk's bid for Metsera in high-stakes pharma clash
05:15am, Saturday, 01'st Nov 2025
Pfizer has escalated its fight for obesity biotech Metsera by filing suit against both Metsera and Novo Nordisk in the Delaware Court of Chancery on October 31. The litigation challenges Novo's bombsh
Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera
05:12pm, Friday, 31'st Oct 2025
The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.
